<DOC>
	<DOCNO>NCT01924767</DOCNO>
	<brief_summary>To investigate safety , tolerability , pharmacokinetics pharmacodynamics BI 10773 repeat dose eight day exploration pharmacokinetics pharmacodynamics BI 10773 multiple dosing , include dose proportionality assessment steady state .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Doses BI 10773 Tablets</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male postmenopausal hysterectomised female patient proven diagnosis type 2 diabetes mellitus treat diet exercise maximum two oral antidiabetic agent except thiazolidindiones least one agent take 50 % maximum dose less . 2 . Glycosylated haemoglobin A1 ( HbA1c ) £ 8.5 % screening . 3 . Age &gt; 21 Age &lt; 70 year ( male hysterectomised female patient ) Age &gt; 60 Age &lt; 70 year ( postmenopausal female patient ) 4 . Body Mass Index ( BMI ) &gt; 18.5 &lt; 40 kg/m2 5 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : 1 . Antidiabetic treatment insulin glitazones one oral hypoglycaemic agent ( except 2 agent least one take 50 % maximum dose ) 2 . Fasted blood glucose &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) two consecutive day washout . 3 . Glycosylated haemoglobin A1 ( HbA1c ) &gt; 8.5 % screen 4 . Clinically relevant concomitant disease type 2 diabetes , hyperlipidaemia medically treat hypertension , : Any late stage complication diabetes ( e.g . retinopathy , polyneuropathy , vegetative disorder , diabetic foot ) Renal insufficiency ( calculated creatinine clearance &lt; 80 ml/min/1.73m² ) Cardiac insufficiency NYHA IIIV , myocardial infarction , know cardiovascular disease include hypertension &gt; 160/95mmHg ( measure training visit timepoints Day 1 ) , stroke TIA ( Transistoric ischaemic attack ) Neurological disorder ( epilepsy ) psychiatric disorder Acute relevant chronic infection ( e.g . HIV , repeat urogenital infection ) Any gastrointestinal , hepatic , respiratory , endocrine immunological disorder 5 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 6 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) 7 . A history additional risk factor TdP ( torsade de pointes ) ( e.g. , heart failure , hypokalemia , family history sudden death age 50 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>